BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 16567036)

  • 21. Commentary on adjunctive use of testosterone gel with sildenafil for erectile dysfunction.
    Morales A
    J Urol; 2008 May; 179(5 Suppl):S103. PubMed ID: 18405738
    [No Abstract]   [Full Text] [Related]  

  • 22. [New PDE-5 inhibitor for treatment of impotence. 9 out of 10 have erections again].
    MMW Fortschr Med; 2003 Jun; 145(26):59. PubMed ID: 12916343
    [No Abstract]   [Full Text] [Related]  

  • 23. [Erectile dysfunction and phosphodiesterase type 5 inhibitors].
    Roumeguère T; Sternon J; Schulman CC
    Rev Med Brux; 2003 Jun; 24(3):169-75. PubMed ID: 12891884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rates of non-arteritic ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors.
    Tsertsvadze A
    Am J Ophthalmol; 2009 Oct; 148(4):625; author reply 625-6. PubMed ID: 19782802
    [No Abstract]   [Full Text] [Related]  

  • 25. Erectile dysfunction drugs and nonarteritic anterior ischemic optic neuropathy.
    Lee AG; Newman NJ
    Am J Ophthalmol; 2005 Oct; 140(4):707-8. PubMed ID: 16226524
    [No Abstract]   [Full Text] [Related]  

  • 26. Diabetic neuropathy - a further indication for phosphodiesterase type 5 inhibitors?
    Oliver JJ
    Int J Clin Pract; 2006 Sep; 60(9):1026-7. PubMed ID: 16939541
    [No Abstract]   [Full Text] [Related]  

  • 27. Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat.
    de Tejada IS
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S40-2. PubMed ID: 15224136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation and diagnostic testing of erectile dysfunction in the era of phosphodiesterase type 5 inhibitors.
    Jacobsohn K; Wang R
    Asian J Androl; 2007 Jan; 9(1):3-7. PubMed ID: 17187154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Visual loss with erectile dysfunction medications.
    Wooltorton E
    CMAJ; 2006 Aug; 175(4):355. PubMed ID: 16870715
    [No Abstract]   [Full Text] [Related]  

  • 30. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
    Kass DA
    Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
    [No Abstract]   [Full Text] [Related]  

  • 31. Phosphodiesterase inhibitors.
    Boswell-Smith V; Spina D; Page CP
    Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S252-7. PubMed ID: 16402111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of the use of PDE5 inhibitors for erectile dysfunction on the lives of Australian men.
    Matic H; McCabe MP
    Int J Impot Res; 2007; 19(4):418-23. PubMed ID: 17538638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
    Hotston M; Shukla N; Bloor J; Persad R; Jeremy JY
    BJU Int; 2006 Dec; 98(6):1331-2. PubMed ID: 17125493
    [No Abstract]   [Full Text] [Related]  

  • 34. PDE5 inhibitors: looking beyond ED.
    Jackson G
    Int J Clin Pract; 2003 Apr; 57(3):159-60. PubMed ID: 12723713
    [No Abstract]   [Full Text] [Related]  

  • 35. [Effectiveness duration determines selection].
    MMW Fortschr Med; 2006 Jul; 148(29-30):54-5. PubMed ID: 16910411
    [No Abstract]   [Full Text] [Related]  

  • 36. Unexpected insights into pelvic function following phosphodiesterase manipulation--what's next for urology?
    McVary KT
    Eur Urol; 2006 Dec; 50(6):1153-6. PubMed ID: 17045387
    [No Abstract]   [Full Text] [Related]  

  • 37. Non-arteritic anterior ischemic optic neuropathy, erectile dysfunction drugs, and amiodarone: is there a relationship?
    Fraunfelder FW; Shults T
    J Neuroophthalmol; 2006 Mar; 26(1):1-3. PubMed ID: 16518158
    [No Abstract]   [Full Text] [Related]  

  • 38. [Some aspects of erectile dysfunction pathogenesis and treatment in patients with obesity].
    Ametov AS; Teodorovich OV; Kondrat'eva LV; Popova AIu
    Ter Arkh; 2006; 78(2):92-4. PubMed ID: 16613108
    [No Abstract]   [Full Text] [Related]  

  • 39. Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction.
    Dunn ME; Althof SE; Perelman MA
    Int J Impot Res; 2007; 19(2):119-23. PubMed ID: 16738695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How do men perceive erectile dysfunction and its treatment? A qualitative study on opinions of men.
    Low WY; Ng CJ; Choo WY; Tan HM
    Aging Male; 2006 Sep; 9(3):175-80. PubMed ID: 17050117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.